Loading…
Castle Biosciences, Inc. is projected to rise to $27.31 by 2027, a +15% move from its current price of $23.72. CSTL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $23.12 | $23.72 | $24.33 | 0.00% |
| Jul 15 | $22.88 | $23.72 | $24.59 | 0.00% |
| Jul 16 | $22.70 | $23.72 | $24.79 | 0.00% |
| Jul 17 | $22.54 | $23.72 | $24.96 | 0.00% |
| Jul 18 | $22.41 | $23.72 | $25.11 | 0.00% |
| Jul 19 | $22.28 | $23.72 | $25.25 | 0.00% |
| Jul 20 | $22.17 | $23.72 | $25.37 | 0.00% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $22.17 | $23.72 | $25.37 | 0.00% |
| Week 2 | $21.56 | $23.72 | $26.09 | -0.01% |
| Week 3 | $21.10 | $23.72 | $26.66 | -0.01% |
| Week 4 | $20.73 | $23.72 | $27.14 | -0.01% |
| Week 5 | $20.40 | $23.72 | $27.58 | -0.02% |
| Week 6 | $20.11 | $23.72 | $27.97 | -0.02% |
| Week 7 | $19.84 | $23.71 | $28.35 | -0.02% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Castle Biosciences, Inc. is a healthcare company focused on molecular diagnostics. It provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), atopic dermatitis (AD), and uveal melanoma, serving dermatology and gastroenterology markets.
The company offers a portfolio of diagnostic tests including DecisionDx-Melanoma, TissueCypher, AdvanceAD-Tx, DecisionDx-SCC, MyPath Melanoma, and DecisionDx-UM. It was incorporated in 2007 and is headquartered in Friendswood, Texas.
Castle Biosciences, Inc. (CSTL) currently trades at $24.30 with a market cap of $737.02M and a rank of 2751. The stock’s near-term forecast places the average price at $24.30 for 2026, with a low of $18.15 and a high of $30.71, and an implied ROI of 0% under a neutral sentiment.
The forecast progresses over the next years, with 2027 and 2028 showing modest gains (avg $26.32 and $26.23, respectively; ROI 8.3% and 7.9%, sentiment neutral). By 2029 the average price rises to $34.01 with a max of $48.17 and a strong bullish signal emerging (ROI 40%). The 2030 forecast aggregates to an average of $39.68 with a max of $57.55, yielding a 63.3% ROI and bullish sentiment.
Longer-horizon projections enlarge the upside further: 2031 avg $39.29 (ROI 61.7%), 2032 avg $42.39 (ROI 74.4%), 2033 avg $42.88 (ROI 76.5%), 2034 avg $44.60 (ROI 83.5%), and 2035 avg $52.70 (ROI 116.9%) with continued bullishness. By 2040 the average price is forecast at $68.52 (max $115.18, ROI 182%), and by 2050 the average is $153.36 (max $281.72, ROI 531.1%), signaling substantial long-term upside alongside rising confidence.
A major floor 25.3% below — a decisive break under it would weaken the trend.
The nearest floor, 16.9% below — buyers have tended to step in here.
The nearest ceiling, 4.2% above — a clean break opens room to run.
A major ceiling 18.8% above — clearing it would confirm fresh momentum.
Key CSTL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CSTL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $23.99 | Sell | $23.97 | Sell |
| MA 10 | $24.12 | Sell | $23.71 | Buy |
| MA 20 | $22.65 | Buy | $23.03 | Buy |
| MA 50 | $21.67 | Buy | $22.81 | Buy |
| MA 100 | $23.99 | Sell | $24.42 | Sell |
| MA 200 | $28.74 | Sell | $25.81 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.66 | Neutral |
| Stoch RSI (14) | 32.80 | Neutral |
| CCI (20) | 47.50 | Neutral |
| Williams %R (14) | -28.21 | Info |
| MACD (12,26,9) | 0.12 | Buy |
| ROC (12) | 10.94 | Buy |
| Bollinger %B (20,2) | 0.67 | Neutral |
| Stochastic %K (14) | 71.79 | Neutral |
| TRIX (15) | 0.47 | Buy |
| Awesome (5,34) | 2.11 | Buy |
| Ultimate (7,14,28) | 55.22 | Neutral |
| Momentum (10) | 0.81 | Buy |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 23.92 | Sell |
| ADX (14) | 18.56 | Neutral |
| ATR (14) | 0.56 | Info |
The near-term technical picture remains bullish in sentiment. The RSI(14) sits at 60, suggesting room for upside with a measured pace. The stock is trading above the 50-day simple moving average of $21.79 and below the 200-day simple moving average of $28.68, indicating a mixed near-term dynamic.
In the short run, the 30-day range spans from $20.36 to $29.00, outlining a broad trading corridor. Key levels to watch are a support at $18.15 and a resistance at $22.91, which help delineate immediate downside and upside pressures as price action evolves.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $18.15 | $23.72 | $29.94 | 0% | Neutral | |
| $21.87 | $27.31 | $35.98 | +15% | Neutral | |
| $22.39 | $28.68 | $39.13 | +21% | Bullish | |
| $28.29 | $37.02 | $51.90 | +56% | Bullish | |
| $33.15 | $44.20 | $63.42 | +86% | Bullish | |
| $33.51 | $45.46 | $66.54 | +92% | Bullish | |
| $35.29 | $48.65 | $72.51 | +105% | Bullish | |
| $36.27 | $50.75 | $76.89 | +114% | Bullish | |
| $38.68 | $54.90 | $84.43 | +131% | Bullish | |
| $45.02 | $64.77 | $101.02 | +173% | Bullish | |
| $58.59 | $89.61 | $148.22 | +278% | Bullish | |
| $120.35 | $204.36 | $368.35 | +762% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $18.15 | $23.72 | $27.84 | +0.00% |
| August 2026 | $19.56 | $23.04 | $27.85 | -2.85% |
| September 2026 | $19.99 | $23.71 | $28.95 | +2.89% |
| October 2026 | $20.28 | $24.18 | $29.79 | +1.98% |
| November 2026 | $19.87 | $23.81 | $29.55 | -1.52% |
| December 2026 | $19.91 | $23.96 | $29.94 | +0.64% |
Click any year to see its month-by-month CSTL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Castle Biosciences, Inc.'s 2026 outlook centres on $23.72, within a $18.15 to $29.94 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CSTL could reach as high as $35.98, with a base case around $27.31 and support toward $21.87 — roughly +15% from $23.72. Price action looks broadly range-bound.
Expect CSTL to range from $22.39 to $39.13 through 2028. The $28.68 average target implies a +21% move from current prices. That is up +5% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The CSTL price prediction for 2029 points to an average of $37.02 (low $28.29, high $51.90) — a potential gain of +56% on today's $23.72. Momentum favours further upside here.
In 2030, CSTL is projected to trade between $33.15 and $63.42, averaging $44.20 — a potential gain of +86% from today's $23.72. That is up +19% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Castle Biosciences, Inc.'s 2031 outlook centres on $45.46, within a $33.51 to $66.54 range. That is up +3% on the projected 2030 average. That marks a +92% change versus current levels. Momentum favours further upside here.
By 2032, CSTL could reach as high as $72.51, with a base case around $48.65 and support toward $35.29 — roughly +105% from $23.72. Buyers look set to stay in control over this stretch.
Expect CSTL to range from $36.27 to $76.89 through 2033. The $50.75 average target implies a +114% move from current prices. That is up +4% on the projected 2032 average. Momentum favours further upside here.
The CSTL price prediction for 2034 points to an average of $54.90 (low $38.68, high $84.43) — a potential gain of +131% on today's $23.72. Buyers look set to stay in control over this stretch.
In 2035, CSTL is projected to trade between $45.02 and $101.02, averaging $64.77 — a potential gain of +173% from today's $23.72. That is up +18% on the projected 2034 average. Momentum favours further upside here.
Castle Biosciences, Inc.'s 2040 outlook centres on $89.61, within a $58.59 to $148.22 range. That is up +38% on the projected 2035 average. That marks a +278% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CSTL could reach as high as $368.35, with a base case around $204.36 and support toward $120.35 — roughly +762% from $23.72. Momentum favours further upside here.
Investing $1,000 in CSTL today (≈ 42.158516 CSTL) could be worth
$8,615.4
+$7,615.4 (+762%) by 2050 · US Dollar
Based on the average projected CSTL price of $204.36 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CSTLwould be worth at today's price.
$1,000 invested in CSTL on Jul 10, 2025 (≈ 50.403225 CSTL) would be worth
$1,195.56
+$195.56 (+19.6%) today · 1.20× · US Dollar
Based on a CSTL entry price of $19.84 vs. today's $23.72.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $24.11 | $983.82 | -1.6% |
| 1 month ago | $21.08 | $1,125.24 | +12.5% |
| 3 months ago | $23.13 | $1,025.51 | +2.6% |
| 6 months ago | $39.66 | $598.08 | -40.2% |
| 1 year ago | $19.84 | $1,195.56 | +19.6% |
| All time (5.0y) ago | $66.8 | $355.09 | -64.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CSTL forecast.
Our base-case forecast reaches $47.00 around 2032.
Implied market cap at $47.00: $1.43B
The multi-year forecast depicts a clear path to higher levels after 2026, with meaningful upside by 2030 and substantial acceleration by 2040 and 2050. The average forecast for 2030 is $39.68 with a max of $57.55 (63.3% ROI) and a bullish outlook. By 2040, the average is projected to $68.52 with a max of $115.18 (182% ROI), and by 2050, the average is forecast at $153.36 with a max of $281.72 (531.1% ROI).
The sequence shows steady gains in the later years, with 2035 at $52.70 (116.9% ROI) and 2032–2034 all showing bullish sentiments. While the long-run numbers imply significant upside potential, these figures are estimates and not guarantees, and outcomes depend on market dynamics and other factors outside the forecast. The near-term outlook remains neutral to gradually positive before the more substantial multi-year upside unfolds.
Tap a question to reveal the answer.
2030 forecast: average price $39.68, range $29.48 to $57.55, ROI 63.3%, sentiment BULLISH.
Near-term outlook for 2026 shows average $24.30 with ROI 0% and NEUTRAL sentiment; longer-term forecasts show rising averages (e.g., 2029 $34.01, 2030 $39.68, 2040 $68.52, 2050 $153.36) with Bullish sentiment and higher ROIs (up to 531.1% by 2050). These are estimates, not guarantees.
yes—the 2030 max is $57.55, and 2029 max is $48.17; 2031 max is $58.18. This indicates the potential to exceed $50 by 2030 under the forecast.
Current price is $24.30. Market capitalization is $737.02M.
2040 forecast: average price $68.52, max $115.18, ROI 182%, sentiment BULLISH.
Castle Biosciences, Inc. Community Discussion
0Share your Castle Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.